Peak Pharmaceuticals, Inc. Updates Ticker To PKPH Completing Its Recent Brand Repositioning

BOULDER, CO--(Marketwired - February 05, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (formerly OTCQB: CTCO), ("Peak Pharma" or the "Company"), a growth stage company aiming to become a leader in the research, development, sales and marketing of safe, hemp-based, medicinal products and supplements, today announced that pursuant to its previously announced name change, the Company has been advised by the Financial Industry Regulatory Authority (FINRA) that effective February 5, 2015, Peak Pharmaceuticals' common stock is listed for quotation on OTC Markets under the symbol "PKPH."

Peak Pharma effected the name change in order to realign its brand and corporate identity with its business operations and growth strategies. "As the company evolved, and our strategy to develop into a leader in the nutraceutical and supplement industry solidified, it became clear our mission would be better served under our revised brand," stated Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang.

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.

ON BEHALF OF THE BOARD,
Soren Mogelsvang, President & CEO
Peak Pharmaceuticals, Inc.